NCT04052555 - Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

April 24, 2026

Study Completion Date

April 24, 2026

Conditions

Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast CarcinomaRecurrent Breast CarcinomaTriple-Negative Breast Carcinoma

Interventions

DRUG

Berzosertib

Given IV

PROCEDURE

Biospecimen Collection

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

RADIATION

Radiation Therapy

Undergo RT

Trial Locations (14)

10065

NYP/Weill Cornell Medical Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

55905

Mayo Clinic in Rochester, Rochester

84025

Farmington Health Center, Farmington

84106

University of Utah Sugarhouse Health Center, Salt Lake City

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

85054

Mayo Clinic Hospital in Arizona, Phoenix

85259

Mayo Clinic in Arizona, Scottsdale

95817

University of California Davis Comprehensive Cancer Center, Sacramento

32224-9980

Mayo Clinic in Florida, Jacksonville

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

77555-0565

University of Texas Medical Branch, Galveston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH